Nifedipine — Calcium channel blocker. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Nifedipine
Class
Calcium channel blocker
Mechanism
Inhibits calcium influx, dilating coronary arteries and arterioles and inhibiting coronary artery spasm.
Used for
Vasospastic angina meeting the specified diagnostic criteria or with a suspected vasospastic component; Chronic stable angina despite adequate beta-blocker and/or nitrate treatment, or when those agents cannot be tolerated; Hypertension, for the cited extended-release tablets
Common side effects
Edema; Headache; Flushing; Asthenia; Palpitations
Warnings
Hypersensitivity to nifedipine (contraindicated)
Interactions
Beta blockers: reports of increased heart failure, severe hypotension or worsening angina with the combination; Long-acting nitrates: the label permits coadministration, but controlled studies of the combination’s antianginal efficacy are lacking
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260804 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Dihydropyridine calcium antagonist that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.
On both cards: Common side effects — Edema; Flushing; Palpitations
Only on the Amlodipine card: Used for — Hypertension; Symptomatic treatment of chronic stable angina; Confirmed or suspected vasospastic angina; Reduction of angina hospitalization or coronary revascularization risk in patients with recently angiographically documented coronary artery disease, without heart failure or an ejection fraction below 40% · Common side effects — Dizziness · Warnings — Symptomatic hypotension; Worsening angina or acute MI; Severe hepatic impairment · Interactions — CYP3A inhibitors; Simvastatin; Cyclosporine, tacrolimus
Mechanism: Inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a precursor of cholesterol.
On both cards: Common side effects — Headache; Asthenia
Only on the Rosuvastatin card: Used for — As an adjunct to diet to lower LDL cholesterol in adults with primary hyperlipidemia and to slow atherosclerosis progression in adults; Reduction of major cardiovascular events in adults without established coronary disease who meet the label's age, hsCRP of at least 2 mg/L and additional-risk-factor criteria; Heterozygous familial hypercholesterolemia in adults and children aged 8 years and older, as an adjunct to diet; Homozygous familial hypercholesterolemia in adults and children aged 7 years and older, with other LDL-lowering treatment or alone when unavailable · Common side effects — Nausea; Myalgia; Constipation · Warnings — Myopathy / rhabdomyolysis; Immune-mediated necrotizing myopathy; Acute liver failure or decompensated cirrhosis · Interactions — Cyclosporine, gemfibrozil; Aluminum/magnesium hydroxide antacids; Warfarin
Mechanism: The precise mechanism is incompletely understood; hydralazine apparently lowers blood pressure through direct vascular smooth-muscle relaxation and altered cellular calcium handling, preferentially dilating arterioles.
On both cards: Common side effects — Headache; Palpitations
Only on the Hydralazine card: Used for — Essential hypertension · Common side effects — Tachycardia; Nausea; Angina pectoris · Warnings — Coronary artery disease (contraindicated); Mitral valvular rheumatic heart disease (contraindicated); A lupus-like syndrome, sometimes involving glomerulonephritis, can occur
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera